From Clinical Pioneer to Global Advocate: What 5 Years in a Heart Trial Taught Me About Resilience
- maryrburrell
- 16 minutes ago
- 3 min read
In January 2021, I took a step into the unknown. If you had looked at my medical chart back then, you would have seen the clinical reality: torrential tricuspid regurgitation. But charts don’t capture what it actually feels like to live with a failing heart valve the exhausting fatigue, the shrinking of your daily world, and the heavy weight of knowing your options are running out.
Then came an opportunity to participate in the #TriscendII Early Feasibility clinical trial
This wasn't a casual leap of faith; it was direly needed. There was no other choice it was this possibility, or sure death.
Fast forward to March 2026.
A few months ago, I walked into my clinic and completed my final, official appointment for the TRISCEND II study. Five years. More than sixty months of echocardiograms, check-ups, quality-of-life assessments, and data points. Every single one of those appointments required traveling four-plus hours each way to the facility. But I made the trip, time and time again, because I knew the data we were collecting wasn't just for my own survival it was the foundational map for everyone coming after me. What researchers call data, I experienced as a second chance at life.
Closing this five-year chapter proves something that clinical metrics alone cannot fully capture. Back then, I was looking at an absolute dead end. Today, I am living proof that this intervention completely rewrote my trajectory.
But as I look back on this five-year milestone, I realize something profound about the nature of modern medicine: We are not merely the beneficiaries of medical innovation; we are its vital co-authors.
Clinical trials measure leaks, pressures, and volumes. Those numbers matter, they are the exact data points that helped secure CE Mark in Europe and historic FDA approval here in the United States. Because my cohort stayed the course and leaned into the science, thousands of patients with severe tricuspid regurgitation now have a lifeline that didn’t exist when I was diagnosed.
But what the clinical data cannot fully capture is the return of joy. It can’t measure the energy it takes to launch a mentoring organization, the breath required to host a podcast, or the stamina to travel across the globe to advocate for others. The data proves the science, but the patient's story proves the purpose.
Completing the study in March wasn't an ending; it was a commencement. Today, my role has shifted from clinical trial participant to global healthcare strategist. Through my patient led organization, HeartBridge Collective and my position on the first-ever Edwards Lifesciences Patient Council, I am leveraging not just the five years of this clinical trial, but nearly four decades of navigating the healthcare system from the inside. I am taking that lifetime of lived experience and using it to directly shape industry operations and patient advocacy. Together, we are bridging the gap between clinical data and human compassion, ensuring the patient’s voice actively drives medical innovation rather than being treated as an afterthought.
To anyone staring down a diagnosis that shakes your world: don’t let the system convince you that you’re small. Breakthroughs don’t happen because technology magically advances. They happen because patients push, question, persist, and refuse to disappear when the stakes are life or death. Your voice, your story, and your determination are part of what moves medicine forward. You are part of the engine that drives progress. Stand in that power.
My trial may be over, but the advocacy is just getting started.
Share Your Thoughts
If you are a fellow patient, a caregiver, or a healthcare innovator, I’d love to hear from you. How can we better bring the patient voice to the center of healthcare? Let's connect in the comments below.
Comments